Monte Rosa Company Insiders

GLUE Stock  USD 5.78  0.06  1.03%   
Monte Rosa employs about 133 people. The company is managed by 14 executives with a total tenure of roughly 311 years, averaging almost 22.0 years of service per executive, having 9.5 employees per reported executive. Evaluation of Monte Rosa's management performance can provide insight into the firm performance.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Monte Rosa Management Team Effectiveness

The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6123) %, meaning that it created substantial loss on money invested by shareholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities.

Monte Rosa Workforce Comparison

Monte Rosa Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,380. Monte Rosa holds roughly 133 in number of employees claiming about 6% of equities under Health Care industry.

Monte Rosa Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monte Rosa insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monte Rosa's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Monte Rosa insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Monte Rosa Notable Stakeholders

A Monte Rosa stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Monte Rosa often face trade-offs trying to please all of them. Monte Rosa's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Monte Rosa's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Markus MDCEO PresidentProfile
Filip MDChief OfficerProfile
Jennifer ChampouxVP OperationsProfile
Sharon TownsonChief OfficerProfile
Edmund DunnVice ControllerProfile
John CastleChief ScientistProfile
Magnus DPHILSenior DevelopmentProfile
Philip JDGeneral CounselProfile
Andrew FunderburkSenior FinanceProfile
JD MBAChief OfficerProfile
Ajim CFAChief OfficerProfile
Owen WallaceChief OfficerProfile
Silvia BuonamiciVP BiologyProfile
Phil JDG CounselProfile

About Monte Rosa Management Performance

The success or failure of an entity such as Monte Rosa Therapeutics often depends on how effective the management is. Monte Rosa management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Monte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Monte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 93 people.
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.

Monte Rosa Workforce Analysis

Traditionally, organizations such as Monte Rosa use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Monte Rosa within its industry.

Monte Rosa Manpower Efficiency

Return on Monte Rosa Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1M
Net Loss Per Executive9.7M
Working Capital Per Employee1.4M
Working Capital Per Executive13.5M

Complementary Tools for Monte Stock analysis

When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
CEOs Directory
Screen CEOs from public companies around the world
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA